Ras inhibitor CAPRI enables neutrophil-like cells to chemotax through a higher-concentration range of gradients
Neutrophils sense and migrate through an enormous range of chemoattractant gradients through adaptation. Here, we reveal that in human neutrophils, calcium-promoted Ras inactivator (CAPRI) locally controls the GPCR-stimulated Ras adaptation. Human neutrophils lacking CAPRI (caprikd ) exhibit chemoat...
Saved in:
Published in: | Proceedings of the National Academy of Sciences - PNAS Vol. 118; no. 43; pp. 1 - 12 |
---|---|
Main Authors: | , , , , |
Format: | Journal Article |
Language: | English |
Published: |
United States
National Academy of Sciences
26-10-2021
|
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Neutrophils sense and migrate through an enormous range of chemoattractant gradients through adaptation. Here, we reveal that in human neutrophils, calcium-promoted Ras inactivator (CAPRI) locally controls the GPCR-stimulated Ras adaptation. Human neutrophils lacking CAPRI (caprikd
) exhibit chemoattractant-induced, nonadaptive Ras activation; significantly increased phosphorylation of AKT, GSK-3α/3β, and cofilin; and excessive actin polymerization. caprikd
cells display defective chemotaxis in response to high-concentration gradients but exhibit improved chemotaxis in low- or subsensitive-concentration gradients of various chemoattractants, as a result of their enhanced sensitivity. Taken together, our data reveal that CAPRI controls GPCR activation-mediated Ras adaptation and lowers the sensitivity of human neutrophils so that they are able to chemotax through a higher-concentration range of chemoattractant gradients. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Author contributions: X.X. designed research; X.X. contributed new reagents/analytic tools; X.X., X.W., A.M., and S.B. performed research and analyzed data; and X.X. and T.J. wrote the paper. Edited by Philipp Niethammer, Memorial Sloan-Kettering Cancer Center, New York, NY and accepted by Editorial Board Member Carl F. Nathan August 19, 2021 (received for review February 6, 2020) |
ISSN: | 0027-8424 1091-6490 |
DOI: | 10.1073/pnas.2002162118 |